Pharmafile Logo
Pharmafocus logo
Advanced Search

giotrif

Showing 8 posts of 8 posts found.

headquarters_ingelheim3

Additional data for Boehringer’s Giotrif combo shows strong overall survival benefit in lung cancer sub-population

August 5, 2019
Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, giotrif, lung cancer, pharma

German firm Boehringer Ingelheim has released new interim data from a real-world evidence study investigating the efficacy of Giotrif/Gilotrif (afatinib) …

News
birdlr

Boehringer Ingelheim’s Giotrif significantly lowers lung cancer progression in Phase II trials

April 13, 2016
Research and Development AstraZeneca, Boehringer Ingelheim, Iressa, giotrif, lung cancer

German drugmaker Boehringer Ingelheim on Wednesday said a mid-stage study has shown its cancer drug Giotrif (afatinib) reduced the risk …

News
bi_centre_03_2

Boehringer Ingelheim’s Giotrif gets Europan regulatory backing in another lung cancer indication

April 7, 2016
Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, European Commission, giotrif, lung cancer

German drugmaker Boehringer Ingelheim on Thursday said European regulators have granted marketing rights for its non-small cell lung cancer (NSCLC) …

News
BI image

Boehringer and Sanofi admit to code breaches

February 13, 2015
Medical Communications, Sales and Marketing ABPI, Boehringer, PMCPA, Sanofi, afatinib, giotrif

Sanofi and Boehringer Ingelheim have both admitted to breaching the ABPI Code of Practice, with Sanofi set to be publicly …

News

Boehringer blood cancer drug scores in Phase II

July 9, 2014
Research and Development, Sales and Marketing Boehringer, blood, giotrif, leukaemia, volasertib

Less than a year after securing its first cancer drug on the market with Giotrif, Boehringer has taken another decisive …

News
boehringer image

Boehringer lung cancer drug shows survival benefit

June 3, 2014
Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer

A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …

News
boehringer_angle_22

Giotrif increases lung cancer survival

May 16, 2014
Research and Development, Sales and Marketing Boehringer, Iressa, Roche, Tarceva, afatinib, giotrif, lung cancer

Boehringer Ingelheim is trumpeting overall survival results from a new analysis of two late-stage studies involving Giotrif in lung cancer …

News

Boehringer’s first cancer drug gains NICE yes

March 17, 2014
Sales and Marketing Boehringer, Cancer, NICE, NSCLC, afatinib, giotrif

NICE is recommending that Boehringer Ingelheim’s first oncology treatment Giotrif be funded by the NHS. The new final draft guidance …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023